These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10585589)

  • 1. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
    Durrant LG; Buckley DJ; Robins RA; Spendlove I
    Int J Cancer; 2000 Jan; 85(1):87-92. PubMed ID: 10585589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
    Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
    Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
    Buckley DT; Robins AR; Durrant LG
    Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity.
    Durrant LG; Buckley DJ; Spendlove I; Robins RA
    Hybridoma; 1997 Feb; 16(1):23-6. PubMed ID: 9085124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses.
    Durrant LG; Parsons T; Moss R; Spendlove I; Carter G; Carr F
    Int J Cancer; 2001 May; 92(3):414-20. PubMed ID: 11291080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
    Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
    Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.
    Maxwell-Armstrong CA; Durrant LG; Robins RA; Galvin AM; Scholefield JH; Hardcastle JD
    Gut; 1999 Oct; 45(4):593-8. PubMed ID: 10486371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
    Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
    Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Kallmeyer C; Pritchard-Jones K; Durrant LG
    Clin Immunol; 2008 Aug; 128(2):148-54. PubMed ID: 18508409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours.
    Durrant LG; Doran M; Austin EB; Robins RA
    Int J Cancer; 1995 Mar; 61(1):62-6. PubMed ID: 7705934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
    Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
    Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
    Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies designed as effective cancer vaccines.
    Metheringham RL; Pudney VA; Gunn B; Towey M; Spendlove I; Durrant LG
    MAbs; 2009; 1(1):71-85. PubMed ID: 20046577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.
    Maxwell-Armstrong C
    Ann R Coll Surg Engl; 2002 Sep; 84(5):314-8. PubMed ID: 12398121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma.
    Pritchard-Jones K; Spendlove I; Wilton C; Whelan J; Weeden S; Lewis I; Hale J; Douglas C; Pagonis C; Campbell B; Alvarez P; Halbert G; Durrant LG
    Br J Cancer; 2005 Apr; 92(8):1358-65. PubMed ID: 15798769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.